Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial.
Abstract
The randomized, double-blinded Royal Marsden Tamoxifen Breast Cancer Prevention Trial in healthy high-risk women started in 1986 and is still blinded. Eligible participants (<i>n</i> = 2,471) were randomly assigned to tamoxifen (20 mg/d) or placebo for 8 years. Analysis in 2006 showed a 30% risk reduction of estrogen receptor (ER)-positive invasive breast cancer mostly in the posttreatment period. Biomarker analysis in this population may identify any subgroup-specific preventive effects tamoxifen. After a median follow-up of 18.4 years, 242 patients had developed invasive cancer, 134 on placebo and 108 on tamoxifen. From these, 180 tissue blocks were available and ER, progesterone receptor (PgR), Ki67, HER2, and EGFR were immunohistochemically analyzed. A 32% reduction in ER<sup>+</sup> and PgR<sup>+</sup> invasive cancers resulted after 8 years of treatment. Quantitative levels of ER and PgR were lower in the tamoxifen-treated group, significantly so for ER (<i>P</i> = 0.001). These lower ER levels were restricted to the posttreatment period (<i>P</i> = 0.018). Among the ER<sup>+</sup> group, there was a similar proportional decrease in PgR<sup>+</sup> and PgR<sup>-</sup> tumors by tamoxifen. The median levels of Ki67 were similar in both arms. The numbers of HER2-positive and EGFR-positive cancers were higher in the tamoxifen arm but not significantly so. In conclusion, the preventive effects of tamoxifen result in reduced ER-positive but not ER-negative tumors and reduced ER expression in the ER-positive cases largely confined to the posttreatment period. Overall reductions in PgR expression are explained by lower frequency of ER-positive cases. Impact on Ki67, HER2, and EGFR was modest. <i>Cancer Prev Res; 10(3); 171-6. ©2017 AACR</i>.
Subject
Humans
Breast Neoplasms
Tamoxifen
Selective Estrogen Receptor Modulators
Receptor, erbB-2
Ki-67 Antigen
Receptors, Estrogen
Receptors, Progesterone
Immunohistochemistry
Follow-Up Studies
Double-Blind Method
Phenotype
Adult
Aged
Middle Aged
Female
ErbB Receptors
Biomarkers, Tumor
Research team
Medicine (RMH Smith Cunningham)
Endocrinology
Language
eng
Date accepted
2016-12-19
License start date
2017-03
Citation
Cancer prevention research (Philadelphia, Pa.), 2017, 10 (3), pp. 171 - 176
Except where otherwise noted, this item's license is described
as
https://creativecommons.org/licenses/by/4.0
Related items
Showing items related by title, author, creator and subject.
-
A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.
Scott, RA; Freitag, DF; Li, L; Chu, AY; Surendran, P; et al. (AMER ASSOC ADVANCEMENT SCIENCE, 2016-06-01)Regulatory authorities have indicated that new drugs to treat type 2 diabetes (T2D) should not be associated with an unacceptable increase in cardiovascular risk. Human genetics may be able to guide development of antidiabetic ... -
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Rugo, HS; Lerebours, F; Ciruelos, E; Drullinsky, P; Ruiz-Borrego, M; et al. (ELSEVIER SCIENCE INC, 2021-04-01)BACKGROUND: Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer in SOLAR-1; limited data are available ... -
Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
Klampatsa, A; Achkova, DY; Davies, DM; Parente-Pereira, AC; Woodman, N; et al. (ELSEVIER IRELAND LTD, 2017-05-01)Malignant mesothelioma remains an incurable cancer. We demonstrated that mesotheliomas expressed EGFR (79.2%), ErbB4 (49.0%) and HER2 (6.3%), but lacked ErbB3. At least one ErbB family member was expressed in 88% of tumors. ...